The 66th American Society of Hematology (ASH) Annual Conference will be held from December 7th to 10th, 2024 in San Diego, USA, hosted by the American Society of Hematology (ASH). Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has been selected for one presentation at this year's conference - KQ-2003 BCMA/CD19 dual-target CAR-T therapy in patients with relapsed and refractory multiple myeloma (including those with extramedullary disease metastasis). The latest research data will be presented in an oral presentation at the 2024 ASH Annual Conference.
Abstract Title: A prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease.
Abstract Number: 923
Presentation type: Oral
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies
Time: Monday, 9 December 2024, 3：45 PM – 4：00 PM Pacific time
Location: Hall B (San Diego Convention Center)
Abstract Link：https://ash.confex.com/ash/2024/webprogram/Paper201160.html
Presenter: Professor Hua Jiang
About KQ-2003
KQ-2003 is a next-generation dual-target CAR-T cell therapy developed based on Novatim’s enhanced CAR-T platform. Through parallel structural design and optimized signaling domains, KQ-2003 significantly improves CAR-T cell persistence and anti-tumor activity while reducing relapse risks seen in traditional CAR-T therapies. Its core advantages include: outstanding efficacy, superior safety profile, and cost competitiveness. It has achieved promising efficacy and superior safety profile in Phase I trials for relapsed/refractory multiple myeloma (rrMM) and POEMS syndrome.
About Novatim
Founded in 2018, Novatim is a biotechnology company dedicated to the development and clinical application of innovative immuno-oncology therapeutics. Based on unmet clinical needs and differentiated innovation, Novatim has built three core R&D platforms: Bispecific Antibody Platform，Nanobody-based ADC Platform，Enhanced Dual-target CAR-T Platform.
The company has independently developed more than ten novel and differentiated FIC/BIC pipelines from scratch. Based on the bispecific antibody platform, Novatim developed China's first βγ-biased PD-1/IL-2 fusion protein, now in Phase Ib trials in China with IND clearance in both China and the U.S.; Based on the nanobody-ADC platform, Novatim developed the world's first nanobody-based bispecific ADC, currently in Phase Ia in China and IND-cleared in the U.S.; Based on its dual-target CAR-T platform, Novatim developed the world's first enhanced parallel dual-target CAR-T, now in Phase I/IIa clinical trials.
